Anti Money Laundering Global Market Report 2023 – By Product (Compliance Management, Currency Transaction Reporting, Customer Identity Management, Transaction Monitoring), By Component (Software, Services), By Deployment (Cloud, On Premise), By Organization size (Small and Medium Enterprises, Large Enterprises), By End User (BFSI, Government, Healthcare, IT and Telecom, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

The case management refer to methods for managing data relationships, documents, and processes for cases that require action and resolution, such as investigations, service requests, and incidents. The benefits of case management include digital record-keeping decreasing paperwork and centralized data management allowing for remote access. The main components of case management include solutions and services. Case management software and solutions provide external support for any complex process that needs a combination of human tasks and electronic workflow. The case management solutions help enterprises address various business challenges and manage unforeseen, information-centric tasks. They are deployed on-premises or cloud and used for various business functions, which include included service requests, fraud detection and anti-money laundering, incident management, investigation management, and legal workflow management. These solutions are used by industries ranging from including banking, financial services, and insurance (BFSI), government, healthcare, it and telecom, retail, and manufacturing. The global case management market is segmented - 1) By Component: Solution, Services 2) By Business Function: Service Request, Fraud Detection and Anti-Money Laundering, Incident Management, Investigation Management, Legal Workflow Management 3) By Depolyment Mode: Cloud, On-premises 4) By Organisation Site: Small and Medium-sized Enterprises (SMEs), Large Enterprises 5) By Verticals: Banking, Financial Services, and Insurance (BFSI), Government, Healthcare, IT and telecom, Retail, Manufacturing, Other Verticals The global case management market size will grow from $6.57 billion in 2022 to $7.21 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the case management is expected to grow to $10.47 billion in 2027 at a CAGR of 9.8%. The healthcare organizations deploying rectification solutions for various case management are significantly increasing the scope of the case management market. The healthcare organizations and related stakeholders are deploying rectification solutions for various case management mainly to correct and reduce errors in data of cases, protect health records, and other reasons. Due to this increased deployment of rectification solutions for various case management, the demand for case management solutions and services will increase as these are effective solutions to manage data digitally while enabling data protection. Case management supports a complex process that requires a blending of electronic workflow and human tasks to avoid errors. For instance, in April 2022, according to an article published by the Office of the National Coordinator for Health Information Technology, a US government department, as of 2021, approximately four out of every five office-based physicians (78%) and virtually all non-federal acute care hospitals (96%) had implemented a certified EHR. This increase shows a significant 10-year improvement from 2011 when 28% of hospitals and 34% of physicians used an EHR. Thus, the healthcare organizations deploying rectification solutions for various case management will drive the case management market growth. Major players in the case management market are DST Systems, Pegasystems, Kofax, Dell Technologies, Newgen Software, Appian, Micropact, IBM, AINS, Pulpstream, Hyland Software, Northern Case Management, VONA Case Management, PriMedical Inc., and Maximus. Technological advancement is a key trend gaining popularity in the case management market. The market is witnessing the implementation of advanced technologies such as artificial intelligence (AI) in case management solutions to enable automation and streamline the case management functionalities. This AI-based case management software captures customer sentiment, refines cases, and automates functions resulting in better case management and efficient resolutions. Key players are focusing on offering AI-based case management software to strengthen their market position. For instance, Sprinklr, a US-based software company offers AI-powered case management software for the automation of workflows and streamlining case handling. It uses AI, listening and monitoring tools, and unified customer experience management (Unified-CXM) platform to discern the customer sentiment, filter cases, and automate workflows, leading to easy case handling, focused case management, and quick case resolutions. It enhances time-to-resolution, customer satisfaction, and cost-efficiency. In February 2021, AccuRisk Solutions LLC, a US-based general underwriting company acquired Case Management Specialist Inc for an undisclosed amount. This acquisition will help AccuRisk provide cost containment services and high-quality medical management services to the clients across the globe. Case Management Specialists Inc is a US-based independent medical management and wellness company that provides a wide range of services including case management. North America was the largest region in the case management market in 2022. The regions covered in the case management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the case management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The case management market includes revenues earned by entities by providing security of sensitive patient data, clients comprehensive assessment, scheduling, charting, treatment planning, and medical billing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The case management market research report is one of a series of new reports from The Business Research Company that provides case management market statistics, including case management industry global market size, regional shares, competitors with a case management market share, detailed case management market segments, market trends and opportunities, and any further data you may need to thrive in the case management industry. This case management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Anti-viral drug therapy refers to drugs that are used for the treatment of viral infections, such as human immunodeficiency virus (HIV), hepatitis, influenza, and novel coronavirus. Antiviral drugs do not kill their target pathogens, instead, they inhibit the development of those viruses. The anti-viral drug establishments are primarily engaged in the manufacturing of DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. The main types of anti-viral drug therapy are branded and generic. The various drug classes involved are DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others that are used for HIV, hepatitis, herpes, influenza, and others. Reverse-transcriptase inhibitors (RTIs) are a type of antiretroviral medication used to treat HIV infection or AIDS, as well as hepatitis B in some cases. The global antivirals market is segmented – 1) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug Classes 2) By Application: HIV, Hepatitis, Herpes, Influenza, and Other Applications 3) By Type: Branded, Generic The global antivirals market size will grow from $97.14 billion in 2022 to $107.84 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antivirals is expected to grow to $156.99 billion in 2027 at a CAGR of 9.8%. The demand for anti-viral drugs is anticipated to grow at a rapid pace due to the novel coronavirus outbreak. As there are no vaccines and potential treatments for COVID-19, companies are trying to repurpose existing drugs in the fight against the novel coronavirus. The use of certain existing anti-viral drugs for the COVID-19 treatment is contributing to the growth of the anti-viral drugs market. However, if any of these drugs under trial show further promising results in treating the coronavirus infection, the anti-viral market will see further growth. Major players in the anti-viral drug therapy market are AbbVie Inc., Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca PLC., Aurobindo Pharma, Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi, Sanofi, Regeneron Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., Novavax, Inc., and BioCryst Pharmaceuticals, Inc. Increasing public-private funding for life science research globally is expected to drive the growth of the anti-viral drug therapy market. Currently, there are no drugs or vaccines approved for the treatment of COVID-19 disease, however, there are several vaccines and drugs in the pipeline, that are yet to be approved or launched. Governments around the world announced new grant funds for researchers in vaccines, treatment, and diagnostics. In March 2020, the Canadian government announced $214.6 million for coronavirus research. Wellcome and the Gates Foundation announced they are joining forces with the credit card company MasterCard in a $125 million push to speed up the development of drugs for treating COVID-19 infections. Hence increasing public-private funding for life science research will enhance the research and development which drive the growth of the COVID-19 anti-viral drug therapy market. The emergence of alternative therapies such as naturopathy and homeopathy for the treatment of viral infections is negatively affecting the market. The development of COVID-19 anti-viral drugs involves high R&D costs. The development of COVID-19 anti-viral drugs involves high operating costs and requires a greater capital investment. Due to the high R&D costs involved in drug development, there is a growth in the demand for alternative medicines such as naturopathy and homeopathy. Saikosaponins (A, B2, C, and D), which are naturally occurring triterpene glycosides isolated from medicinal plants such as Bupleurum spp., Heteromorpha spp., and Scrophulariascorodonia, exert antiviral activity against HCV-22E9. Saikosaponins inhibit viral attachment and penetration stages. The marketed drugs would be priced much higher than the actual manufacturing costs. Hence using these naturopathy and homeopathy medicines can restrain the market growth. Companies in the anti-viral drug therapy market are continuously innovating through technological advancements to develop drugs to treat different viral infections. Biopharmaceutical companies are developing vaccines for the treatment of novel coronavirus. Technological advances in the pharmaceutical sector include the development of nucleic acid vaccines that are DNA- and RNA-based, and which enable the human body to produce vaccine antigens. In March 2020, Applied DNA Sciences’ subsidiary LineaRx and Takis Biotech formed a joint venture to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine. Such initiatives and activities are projected to support market growth to a significant extent. In February 2020, GeoVax, a US-based pharmaceutical company, and BravoVax, a China-based pharmaceutical company, announced plans to develop a coronavirus cure in the form of a vaccine based on the former’s MVA-VLP vaccine platform. BravoVax will be responsible for testing and manufacturing the vaccine as well as coordinating with the public health and regulatory authorities in China. GeoVax’s Modified Vaccinia Ankara platform enables enhanced expression and stable transgenes during the manufacturing process. Combined with the immunogenicity of Virus-Like Particles (VLPs), the technology enables the production of vaccines. The collaboration between these two companies is to develop a coronavirus vaccine. North America was the largest region in the anti-viral drug therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global antivirals market during the forecast period. The regions covered in the global anti-viral drug therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti-viral drug therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anti-viral drug therapy market research report is one of a series of new reports from The Business Research Company that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiemetics and antinauseants refer to drugs that are used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. Antiemetic and antinauseant drugs prevent, control, or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu, or chemotherapy. These drugs reduced the symptoms of nausea or vomiting by blocking signal messages to the part of the brain that controls nausea and vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonists, antihistamines (h1 histamine receptor antagonists), cannabinoids, and benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists, and others. A dopamine antagonist also referred to as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others and is implemented in various sectors such as hospitals, medical centers, clinics, and research institutes. The global antiemetics and antinauseants market is segmented – 1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types 2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes The global antiemetics and antinauseants market size will grow from $7.76 billion in 2022 to $8.09 billion in 2023 at a compound annual growth rate (CAGR) of 4.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antiemetics and antinauseants is expected to grow to $9.12 billion in 2027 at a CAGR of 3.0%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatments to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by the Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac), and other serotonin 5-HT3 receptor types of antagonists. An increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for the market. Major players in the antiemetics and antinauseants market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Eli Lilly and Company, Merck, Eisai, Bristol-Myers Squibb, and SRS Pharmaceuticals . Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the antiemetics and antinauseants market. Despite the presence of a range of drugs, the practitioners prescribe similar drugs to treat patients with different conditions of nausea. The popularity of only a few drugs leads to lower demand for other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kinds of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specifically targeted sites in a controlled manner through Nanomedicine and Nano delivery systems. Nanomedicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drug manufacturers are inclining more toward the use of Nanomedicine or Nano drugs to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is the first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of the Food and Drug Administration Department of Health and Human Services, U.S. part 336, contains conditions that all Antiemetic and Antinauseant drugs are required to fulfil to remain in the market, such as definitions, regulations, and regulations related to the labelling of the antiemetic drug products. North America was the largest region in the drugs for antiemetics and antinauseants market in 2022. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the global antiemetics and antinauseants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antiemetics and antinauseants market research report are one of a series of new reports from The Business Research Company that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antidepressants refer to a medication that aids in the treatment of depressive symptoms. Additionally, they can aid in the treatment of SAD, other anxiety disorders, and social anxiety disorder. Unpleasant side effects are possible with antidepressants. Initially, signs and symptoms including nausea, weight gain, or sleep issues can be prevalent. The main product types of antidepressants are selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant (TCA), and monoamine oxidase inhibitor (MAOI). SSRIs (selective serotonin reuptake inhibitors) are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various drug class includes monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants that are used for the treatment of the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder. The global antidepressants market is segmented – 1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI) 2) By Drug Class: Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants 3) By Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder The global antidepressants market size grew from $16.44 billion in 2022 to $17.41 billion in 2023 at a compound annual growth rate (CAGR) of 5.9% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antidepressants is expected to grow from $25.52 billion in 2027 at a CAGR of 10.0% . The antidepressants market has also surged during the COVID-19 outbreak. The increasing number of cases and fatalities is affecting mental health by elevating anxiety worldwide. People who are already living with mental health problems are experiencing increased stress levels over the COVID-19 outbreak. This has triggered the demand for antidepressant drugs. Major players in the antidepressants market are Allergan PLC., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC., H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun Pharmaceuticals Pvt Ltd., Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd., Forest laboratories and Akeda Pharmaceutical . Globally, rising cases of mental health disorders are the key factor in the growth of the antidepressant drug industry, as many customers rely on these medications to counter depression, anxiety disorder, and other mental diseases. Antidepressant medications are used in conditions such as depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. Globally, the percentage of people with depression varies from 2% to 6%, and the elderly are at greater risk of depression compared to other age groups. According to WHO, in 2020, about 264 million people of all ages worldwide suffered from depression. Therefore, rising cases of mental health disorders are expected to drive the growth of the antidepressant market. The side effects of antidepressant drugs are a key factor hampering the growth of the antidepressant market. For instance, the antidepressants Lexapro (escitalopram) and Celexa (citalopram), both are used to treat depression and Lexapro also helps for treating anxiety. Lexapro and Celexa can cause side effects common to others which include nausea, sleeplessness, sweating, dry mouth, and drowsiness. Celexa and Lexapro are both at risk for even more serious side effects including excessive bleeding, seizures, and vision issues. Therefore, the side effects of antidepressant drugs are expected to limit the growth of the antidepressant market. The treatment of resistant depression is a key trend in the antidepressant market. Ketamine is the new treatment that is used for anesthesia during surgery, stimulates the development of glutamate, and prompts the brain to form new neural connections. It makes the brain more adaptable and capable of developing new pathways and helps people to create more optimistic thoughts and behaviors. For instance, Food and Drug Administration (FDA) approved a new ketamine depression drug esketamine which is one-half of the ketamine compound. The drug must be administered as a nasal spray and patients must be taking another antidepressant at the same time. Also, the drugs can be prescribed to only those patients who have (unsuccessfully) tried two antidepressants before. In October 2021, ShineCo., Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, and other biotech products, announced that it has entered into a framework agreement to acquire a majority stake in Beijing Wonner Biotech Co., Ltd., for a deal amount of $30 million. Through this acquisition, Shineco aims to jointly develop SNG, a rapid-acting antidepressant natural innovative medicine. Beijing Winner is a biotechnology company based in China that specializes in the research and development of natural medicines and related products. North America was the largest region in the antidepressants market in 2022. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the global antidepressants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antidepressants market research report is one of a series of new reports from The Business Research Company that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Fraud detection and prevention refers to the strategies accepted to discover and avoid attempts to secure money or property by deception. Fraud detection and prevention services help organizations analyze huge and complex data sets to detect anomalies, reduce false positives, and provide end-to-end advanced fraud management solutions. The main types of fraud detection and prevention are check fraud, identity fraud, internet/online fraud, investment fraud, payment fraud, insurance fraud, and other fraud types including mortgage fraud, insider fraud, and mobile fraud. Check fraud refers to automated check image analysis utilizing powerful software to detect small corrections that may not be visible to the human eye alone. These tools look at fixed information on the check such as payer’s details, signature line placement, font, check size, and serial number. The deployment modes used in fraud detection and prevention are on-premise and cloud and the various solutions provided include fraud analytics, authentication, reporting, and visualization. Fraud detection and prevention are used in insurance claims, money laundering, and electronic payment in small and medium enterprises (SMEs), and large enterprises. The global fraud detection and prevention market is segmented - 1) By Fraud Type: Check Fraud, Identity Fraud, Internet /Online Fraud, Investment Fraud, Payment Frauds, Insurance Fraud, Other Fraud Types 2) By Deployment Mode: Cloud, On-premises 3) By Solution: Fraud Analytics, Authentication, Reporting, Visualisation, Other Solutions 4) By Application: Insurance claims, Money laundering, Electronic Payment 5) By End User: Small and Medium Enterprises (SMEs), Large Enterprises The global fraud detection and prevention market size will grow from $33.58 billion in 2022 to $41.91 billion in 2023, at a compound annual growth rate (CAGR) of 24.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global fraud detection and prevention is expected to grow to $102.45 billion in 2027 at a CAGR of 25.0%. An increase in the frequency of cyberattacks and frauds is driving the growth of the fraud detection and prevention market. The International Criminal Police Organization's judgement of the impact of COVID-19 on cybercrime has demonstrated an important target shift from individuals and small businesses to major corporations. For instance, in 2020, according to Interpol, in the pandemic, with businesses and firms immediately installing remote systems and networks to help staff work from home, criminals are taking advantage of enlarged security vulnerabilities to steal data, generate profits, and cause disruption. Within 4 months, from January to April, INTERPOL detected around 48,000 malicious URLs, 737 incidents related to the malware, and 907,000 spam messages. Therefore, the increase in the frequency of cyberattacks and frauds is driving the growth of the fraud detection and prevention market. Major players in the fraud detection and prevention market are IBM Corporation, FICO, Oracle Corporation, SAS Institute, BAE Systems, DXC Technology, SAP SE, ACI Worldwide, Fiserv, Inc., ThreatMetrix Company, NICE System Ltd., F5 Networks Inc., Equifax Inc., Cybersource Corporation, and Global Payments Inc. Technological advancement is a key trend gaining popularity in the fraud detection and prevention market. Technological advancement is the discovery of knowledge that advances the understanding of technology. For instance, in October 2022, DG Financial Technology Inc. (DGFT), a Japan-based service provider company, partnered with Scudetto Corporation, a Japan-based company specializing in online fraud prevention, and launched Sift Digital Trust & Safety Suite (Sift), an artificial intelligence (AI)-built fraud detection solution. Sift is a fraud detection and prevention solution that uses artificial intelligence to detect fraud and abuse in the e-commerce space and online, including credit card fraud and account takeover, to reduce the damage from chargebacks and other fraudulent activities by streamlining fraud prevention operations and increasing revenue. In September 2021, TransUnion, a US-based financial information platform has acquired Neustar for an undisclosed amount. The acquisition is expected to advance TransUnion’s strategy to expand from its credit solutions with supportive digital marketing and fraud mitigation capabilities. Neustar, Inc., is an American technology company that offers real-time information and analytics for the Internet, risk, and digital performance. North America was the largest region in the fraud detection and prevention market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fraud detection and prevention market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fraud detection and prevention market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fraud detection and prevention market consists of revenues earned by entities that provide protection against fraudulent activities that can involve a broad range of cases such as money laundering, cybersecurity threats, tax evasion, and fraudulent insurance claims. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The fraud detection and prevention market research report is one of a series of new reports from The Business Research Company that provides fraud detection and prevention market statistics, including fraud detection and prevention industry global market size, regional shares, competitors with a fraud detection and prevention market share, detailed fraud detection and prevention market segments, market trends and opportunities, and any further data you may need to thrive in the fraud detection and prevention industry. This fraud detection and prevention market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

RegTech, or regulatory technology, is a set of enterprises that employ cloud computing technology and software-as-a-service (SaaS) to assist businesses in complying with regulations more efficiently and cost-effectively. RegTech's primary functions are regulatory surveillance, monitoring, and compliance. The RegTech IS engaged in providing regulatory processes within the financial industry via advanced technologies. The main types of components in RegTech are solutions and services. The RegTech services reduce the threats such as cyberattacks, security breaches, or money laundering by using regulatory-driven transformations. The different modes of deployment include cloud, on-premises and are deployed in various organization sizes such as large enterprises, small and medium-sized enterprises (SMEs). It is used in risk and compliance management, identity management, regulatory reporting, anti-money laundering (AML) and fraud management, regulatory intelligence, and is implemented in several verticals such as banks, insurance companies, fintech firms, it and telecom, public sector, energy and utilities, others. The global regtech market is segmented - 1) By Component: Solutions, Services 2) By Deployment Type: Cloud, On-Premises 3) By Organization Size: Large Enterprises, Small and Medium-sized Enterprises (SMEs) 4) By Application: Risk And Compliance Management, Identity Management, Regulatory Reporting, Anti-Money laundering (AML) And Fraud Management, Regulatory Intelligence 5) By End User: Banks, Insurance Companies, FinTech Firms, IT And Telecom, Public Sector, Energy And Utilities, Other End Users The global regtech market size will grow from $9.93 billion in 2022 to $12.37 billion in 2023 at a compound annual growth rate (CAGR) of 24.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global regtech is expected to grow to $30.4 billion in 2027 at a CAGR of 25.2%. The rising number of fraudulent activities such as money laundering in the financial sector is expected to propel the growth of the RegTech market in the forecast period. Fraudulent activities such as money laundering have increased and therefore financial organizations need a more powerful RegTech framework that can help risk and compliance teams manage the deluge of ever-increasing regulatory compliance and progressively sophisticated breaches successfully. For example, in 2022, according to a report published by LexisNexis Risk Solutions, a US-based global data and analytics company, the costs of fraud for U.S. and Canadian financial services companies are rising. U.S. financial services companies pay $4.23 instead of $3.64 for every $1 lost to fraud, a 16.2% increase. Canadian financial services companies' costs increased by 19.6%, from $3.16 in 2020 to $3.78 in 2022. Thus, the rising number of fraudulent activities increases the demand for the growth of the RegTech market. Major players in the regtech market are Abside RegTech, Accuity, ACTICO, Acuant Inc., Ascent Technologies Inc., BearingPoint Software Solutions GmbH, Broadridge Financial Solutions Inc., BWise Beheer B.V., Compliance Solutions Strategies, Sysnet Global Solutions, Trulioo, ComplyAdvantage, Fenergo, IBM Corporation, Infrasoft Technologies, Jumio, London Stock Exchange Group plc, MetricStream Inc., NICE Actimize, RIMES Technologies Corporation, and VERMEG. The application of AI, ML, and blockchain technologies has emerged as a key trend in the RegTech market. Major companies operating in the RegTech sector are increasingly adopting AI, ML, and blockchain technologies to automate processes such as data management analysis and due diligence. For instance, in January 2021, Darktrace, a UK-based AI cyber security company launched the fifth version of autonomous response technology for general accessibility, allowing businesses to benefit from the cloud while also safeguarding themselves from new cyber-threats. Compliance with regulations including GDPR, HIPAA, and the DFS Cyber Security Regulations adds to the long list of issues that security professionals face. In November 2022, Regnology, a Germany-based software provider specializing in regulatory reporting solutions, acquired b.fine for an undisclosed amount. This acquisition improves the integration of SupTech and RegTech and leverages powerful connections to provide more automated and standardized procedures to new clients throughout Europe and beyond. b.fine a Belgian RegTech company that helps financial institutions improve the reporting process. North America was the largest region in the regtech market in 2022. The regions covered in the global RegTech market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the regtech market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The RegTech market includes revenues earned by entities by client identification, monitoring, reporting, data protection, data warehousing and analytics, legal and regulatory analysis, training and general compliance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The RegTech market research report is one of a series of new reports from The Business Research Company that provides RegTech market statistics, including RegTech industry global market size, regional shares, competitors with a RegTech market share, detailed RegTech market segments, market trends and opportunities, and any further data you may need to thrive in the RegTech industry. This RegTech market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antifungal drugs refer to drugs that are used to detect and eliminate fungal pathogens. The fungal pathogens thrive in the body in unhygienic and unclean environments. These drugs are also known as antimycotic medications, used to treat and prevent mycoses such as athlete's foot, ringworm, candidiasis (thrush), and serious systemic infections such as cryptococcal meningitis, and others. The main types of drugs in antifungals are echinocandins, azoles, polyenes, and allylamines. Echinocandins are a new type of antifungal medication that works by inhibiting the formation of 1,3-D-glucan, a key component of the fungal cell wall, in an entirely fungal-specific manner. The different routes of administration include oral, parenteral, and topical and involve various therapeutic indications such as aspergillosis, dermatophytosis, candidiasis, and others. The several sectors include hospitals and clinics, dermatology clinics, and other users. The global antifungals market is segmented – 1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines 2) End users: Hospitals & Clinics, Dermatology clinics, Other Users 3) By Route of Administration: Oral, Parenteral, Topical 4) By Therapeutic Indications: Aspergillosis, Dermatophytosis, Candidiasis, Other Therapeutic Indications The global antifungals market size will grow from $31.12 billion in 2022 to $35.19 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market share of the global antifungals is expected to grow to $54.88 billion in 2027 at a CAGR of 11.8%. A point prevalence survey was conducted in Turkey. According to the survey, antifungal drugs were mostly prescribed in pediatrichematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%). The other units prescribing antifungal drugs included pediatric services (18.3%), pediatric ICUs (PICUs) (14.6%), and hematopoietic (HSCT) units (7.3%). According to the same survey, the antifungals were used for prophylaxis in 48.8% of patients and about 50% of patients were treated with antifungal drugs based on observation. Among 50% of patients, who were treated post-observation, around 18.8% of patients have prescribed an antifungal therapy, and 31.2% of patients were targeted for the treatments. Major players in the antifungals market are Pfizer, Novartis, Merck & Co., Bayer Healthcare and Abbott Laboratories, Sanofi-Aventis, Kramer Laboratories, GlaxoSmithKline Gilead, Enzon Pharmaceuticals Inc., and Basilea Pharmaceuticals AG . The increasing prevalence of fungal infections is expected to propel the growth of the antifungals market. Diseases such as SARS, Zika virus, Ebola and COVID-19 have increasingly led to infections in various parts of the world, leading to an increase in the global disease burden. According to the World Health Organization (WHO), in 2022, over the course of the COVID-19 pandemic, the number of fungal infections increased markedly amongst hospitalized patients. In addition, according to a 2022 article published in British weekly scientific journal, Nature, there was a spike in invasive Candida infections in patients with COVID-19 in the intensive care units (ICUs) of Wuhan, China. Additionally, during the second wave of the pandemic, India reported more than 47,500 cases of COVID-19 associated mucormycosis between May and August 2021. Hence, the increasing incidence of fungal infections is expected to drive the antifungals market in the forecast period. Antifungal drug manufacturers are offering skimming prices for branded drugs. The discovery, development, and manufacturing processes of branded drugs generally require high investments. As a result, companies in the market offer branded drugs at the highest initial prices and implement other pricing strategies to ensure the product stays competitive at a high price. Price skimming is a pricing strategy in which a company charges a high initial price and then gradually lowers the price to attract more price-sensitive customers. It is used to maximize profits when a new product is introduced in the market. Manufacturers and marketers of branded drugs should consider adopting the price skimming strategy for branded drugs. They should price these branded drugs high to recover the high costs incurred during drug development and manufacturing. Drug developers and manufacturers are scaling up the various departments such as research and development, marketing, and manufacturing through collaborations and strategic partnerships with other companies and research institutes, to expand their product portfolios. So, companies in the anti-infective drugs market should consider strategic collaborations to broaden their scope and product portfolios to increase revenues and stay competitive in the market. North America was the largest region in the drugs for antifungals market in 2022. The Middle East is expected to be the fastest-growing region in the global antifungals market share. The regions covered in the global antifungals market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antifungals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antifungal market consists of sales of clotrimazole, miconazole, and ketoconazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antifungals market research report is one of a series of new reports from The Business Research Company that provides antifungals market statistics, including antifungals industry global market size, regional shares, competitors with antifungals market share, detailed antifungals market segments, market trends, and opportunities, and any further data you may need to thrive in the antifungals industry. This antifungals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antidiarrheal drugs refer to drugs that relieve the frequent passing of a watery, loose stool, one of the symptoms of diarrhoea. According to their shared chemical or functional properties, antidiarrheal medications can generally be grouped into three groups: adsorbents, antimotility agents, and bacterial replacements (probiotics). The main classes of antidiarrhoeals drugs are mucosal protectants and motility modifying drugs. Mucosal protective agents are drugs that safeguard the stomach’s mucosal lining from gastric acid and are employed to cure peptic ulcers. The different types include OTC drugs, and prescription drugs, which are used by adults and children. The global antidiarrhoeals market is segmented – 1) By Drug Class: Mucosal Protectants, Motility Modifying Drugs 2) By Application: Adults, Childrens 3) By Type: OTC drugs, Prescription Drugs The global antidiarrhoeals market size will grow from $3.81 billion in 2022 to $3.94 billion in 2023 at a compound annual growth rate (CAGR) of 3.5% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antidiarrhoeals is expected to grow to $4.31 billion in 2027 at a CAGR of 2.3% . The rise in the number of diarrhea cases significantly contributes to the growth of the antidiarrheal drug market. According to UNICEF, diarrhea was the second leading cause of death among children under the age of 5 years that is responsible for killing 760,000 children every year. An increasing number of diarrheal cases increases the demand for antidiarrheal drugs market. Major players in the antidiarrhoeals market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals, Merck & Co., Pfizer, Proctor & Gamble, Sanofi Aventis and Bayer. An increase in the use of biologics medicines poses to be a restraint to the antidiarrheal market. Biologics are medicines derived from living organisms like human beings, animals, or other microorganisms using biotechnology and are composed of proteins, sugar, nucleic acids, or a combination of each of these substances. Due to their ability to target inaccessible parts using small-molecule therapies, biologics are being preferred over traditional chemical drugs. This shift is restricting the antidiarrheal drugs market hampering its growth of the market. For example, to treat Crohn’s Disease, antidiarrheal medications were being used previously, but with the advent of biologics, demand for antidiarrheal diseases has subsided. Major companies in the antidiarrheal drug market are merging with other companies in the market to increase their reach and market share. Companies merge with or acquire other companies to expand their market share, diversify their product portfolio, or acquire new technologies. For instance, GlaxoSmithKline agreed to acquire Novartis AG's 36.5% stake in the consumer healthcare business for $ 13 billion to expand the market. The antidiarrheal drug industry is governed by regulatory frameworks by agencies such as US Food and Drug Administration Agency (FDA). FDA's guidelines for antidiarrheal drugs are mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 335 which gives guidelines for the over-the-counter (OTC) human use of the antidiarrheal drugs. Subpart C of the regulation focuses on the labeling aspect of such drugs and mandates a statement of identity, which identifies the product is to be used for diarrhea to avoid any improper use of the drug. The FDA also regulates the warnings and directions of use of the drugs which are to be printed on the cover of these drugs. In March 2020, Arcadia Consumer Healthcare, Inc., a USA-based pharmaceutical company acquired the Kaopectate brand from Sanofi for an undisclosed amount. This acquisition enhanced Sanofi’s product portfolio by providing consumers with simple, efficacious, and high-quality solutions. Sanofi, is a France-based biopharmaceutical company focused on human health. North America was the largest region in the antidiarrhoeals market in 2022. The regions covered in the global antidiarrhoeals market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antidiarrhoeals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antidiarrheal drugs market consists of sales loperamide hydrochloride, Bismuth subsalicylate, Pepto Bismol and Imodium. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antidiarrheal drugs market research report is one of a series of new reports from The Business Research Company that provides antidiarrheal drugs market statistics, including antidiarrheal drugs industry global market size, regional shares, competitors with antidiarrheal drugs market share, detailed antidiarrheal drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antidiarrheal drugs industry. This antidiarrheal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.